Inho Kim

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.

Wan-Jen Hong, Shaji K. Kumar, P. Moreau, 2020, The Lancet. Oncology.